Personalis, Inc. (PSNL) Q3 2025 Earnings Call Transcript
Personalis, Inc. ( PSNL ) Q3 2025 Earnings Call November 4, 2025 5:00 PM EST Company Participants Christopher Hall - President, CEO & Director Aaron Tachibana - CFO & COO Richard Chen - Executive VP of R&D and Chief Medical Officer Conference Call Participants Caroline Corner - Westwicke Partners, LLC Thomas Flaten - Lake Street Capital Markets, LLC, Research Division Mark Massaro - BTIG, LLC, Research Division Daniel Brennan - TD Cowen, Research Division Thomas VonDerVellen - Guggenheim Securities, LLC, Research Division Michael Matson - Needham & Company, LLC, Research Division John Wilkin - Craig-Hallum Capital Group LLC, Research Division Yu He - H.C. Wainwright & Co, LLC, Research Division Presentation Operator Good afternoon, and welcome to the Personalis Third Quarter 2025 Earnings Conference.
Personalis (PSNL) Reports Q3 Loss, Tops Revenue Estimates
Personalis (PSNL) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to a loss of $0.64 per share a year ago.
Personalis (PSNL) Moves 20.5% Higher: Will This Strength Last?
Personalis (PSNL) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Down 27.6% in 4 Weeks, Here's Why You Should You Buy the Dip in Personalis (PSNL)
The heavy selling pressure might have exhausted for Personalis (PSNL) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
After Plunging 30.5% in 4 Weeks, Here's Why the Trend Might Reverse for Personalis (PSNL)
Personalis (PSNL) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
All You Need to Know About Personalis (PSNL) Rating Upgrade to Buy
Personalis (PSNL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Personalis, Inc. (PSNL) Q2 2025 Earnings Call Transcript
Personalis, Inc. (NASDAQ:PSNL ) Q2 2025 Earnings Conference Call August 5, 2025 5:00 PM ET Company Participants Aaron L. Tachibana - CFO & COO Christopher M.
Personalis (PSNL) Surges 14.2%: Is This an Indication of Further Gains?
Personalis (PSNL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Personalis (PSNL) Soars 7.3%: Is Further Upside Left in the Stock?
Personalis (PSNL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Personalis, Inc. (PSNL) Q1 2025 Earnings Call Transcript
Personalis, Inc. (NASDAQ:PSNL ) Q1 2025 Earnings Conference Call May 6, 2025 5:00 PM ET Company Participants Caroline Corner - Investor Relations Christopher Hall - Chief Executive Officer and President Aaron Tachibana - Chief Financial and Chief Operating Officer Richard Chen - Executive Vice President, R&D, and Chief Medical Officer Conference Call Participants Thomas Flaten - Lake Street Capital William Bonello - Craig-Hallum Vidyun Bais - BTIG Daniel Brennan - Cowen Yuko Oku - Morgan Stanley Swayampakula Ramakanth - H.C. Wainwright Operator Greetings.
Personalis (PSNL) Reports Q1 Loss, Tops Revenue Estimates
Personalis (PSNL) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to loss of $0.26 per share a year ago.
Hanover Insurance Set to Report Q1 Earnings: What to Expect
THG's Q1 results are likely to reflect a reduction in Personal Lines policy count in the Midwest and the implementation of deductibles in most of Personal Lines.
